Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2022-01-01
Serija:Cancer Treatment and Research Communications
Teme:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Online dostop:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki